Avecho Biotechnology (ASX: AVE): A $45M Biotech, a Sandoz Deal & a Phase 3 Readout in Weeks — Dr Paul Gavin

Avecho Biotechnology (ASX: AVE) is heading into one of the nearest-term binary catalysts on the ASX: the interim analysis of its pivotal Phase 3 insomnia trial, due late June. In this Sharewise webinar, Wei Sim sits down with Avecho CEO Dr Paul Gavin to unpack the science, the strategy and the setup behind a ~$45M-market-cap biotech with a global pharma partner already locked in. Avecho has spent six years developing a proprietary cannabidiol (CBD) capsule enhanced with its own TPM drug-delivery technology, which increases CBD absorption roughly four-fold versus the only existing pharmaceutical CBD product, Epidiolex. The target indication — insomnia — affects an estimated 10–30% of the population, and Avecho is aiming to become the world's first pharmaceutical CBD product registered with the TGA, and uniquely, available over-the-counter. Dr Gavin explains the trial design that he argues separates Avecho from the wave of medicinal-cannabis trials that failed: dual primary endpoints (Insomnia Severity Index and sleep efficiency, only one needs to succeed), an adaptive interim analysis, and a two-week placebo run-in to strip out high placebo responders. He also walks through the Sandoz licensing deal (US$3M upfront, up to US$16M in milestones, 14–19% tiered royalties), the regulatory "carrot" the TGA has dangled for OTC registration, the patent moat around the TPM formulation out to 2043, and a potentially accelerated US FDA pathway under recent single-Phase-3 rule changes. The conversation closes on commercialisation timelines, label-expansion potential into anxiety, depression, pain, IBS/IBD, osteoarthritis and menopause, capital strategy if a second cohort is required, and the long-term M&A endgame. Whether the trial succeeds is not guaranteed — and Dr Gavin says so plainly. This is a clear-eyed look at the bull case, the risks, and why a Phase 3 readout is exactly the moment biotech investors pay attention. 🎙️ Guest: Dr Paul Gavin, CEO, Avecho Biotechnology (ASX: AVE) 🎙️ Host: Wei Sim, Sharewise ⚠️ This podcast is general information only and is not financial or investment advice. It does not consider your objectives, financial situation or needs. Pre-revenue, single-catalyst biotech stocks carry significant risk, including total loss of capital. Do your own research and consider consulting a licensed financial adviser. The host and/or affiliated entities may receive fees in connection with companies discussed — see full disclosures.